Baird Ups Meridian Bioscience to Outperform from Neutral

Says that recent stock price weakness has created attractive buying opportunity

Robert W. Baird upgraded Meridian Bioscience (VIVO ) to outperform from neutral, explaining that recent stock price weakness has created attractive buying opportunity.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.